Pharmacovigilance project celebrates success

Following successful completion of a pilot phase, the BC-CfE Pharmacovigilance project became an ongoing initiative to ensure the safe use of antiretroviral therapy in BC. This was particularly important in preparation for the STOP HIV/AIDS program. The scaling up of HIV therapy across BC required evidence of safety and confidence that there would be no unintended harm to the population taking antiretrovirals.

Read the full article

Click here to learn more about antiretroviral safety

Leave a Reply

Scroll to Top

The British Columbia Centre for Excellence in HIV/AIDS Laboratory has discontinued gp-41 resistance testing as T-20 (enfuvirtide/Fuzeon) is no longer available in Canada as of March 31, 2025